Your browser doesn't support javascript.
loading
Overexpression of Igf2-derived Mir483 inhibits Igf1 expression and leads to developmental growth restriction and metabolic dysfunction in mice.
Sandovici, Ionel; Fernandez-Twinn, Denise S; Campbell, Niamh; Cooper, Wendy N; Sekita, Yoichi; Zvetkova, Ilona; Ferland-McCollough, David; Prosser, Haydn M; Oyama, Lila M; Pantaleão, Lucas C; Cimadomo, Danilo; Barbosa de Queiroz, Karina; Cheuk, Cecilia S K; Smith, Nicola M; Kay, Richard G; Antrobus, Robin; Hoelle, Katharina; Ma, Marcella K L; Smith, Noel H; Geyer, Stefan H; Reissig, Lukas F; Weninger, Wolfgang J; Siddle, Kenneth; Willis, Anne E; Lam, Brian Y H; Bushell, Martin; Ozanne, Susan E; Constância, Miguel.
Afiliación
  • Sandovici I; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Centre fo
  • Fernandez-Twinn DS; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Campbell N; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Cooper WN; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Sekita Y; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Zvetkova I; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Ferland-McCollough D; Medical Research Council Toxicology Unit, University of Leicester, Leicester, UK.
  • Prosser HM; The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK.
  • Oyama LM; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Departmento de Fisiologia, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil.
  • Pantaleão LC; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Cimadomo D; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Laboratory of Developmental Biology, Department of Biology and Biotechnology "Lazzaro Spallanzani," University of Pavia, Pavia, Italy.
  • Barbosa de Queiroz K; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Cheuk CSK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.
  • Smith NM; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Kay RG; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Antrobus R; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Hoelle K; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Ma MKL; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Smith NH; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Geyer SH; Center for Anatomy and Cell Biology, Division of Anatomy, Medical University of Vienna, Vienna, Austria.
  • Reissig LF; Center for Anatomy and Cell Biology, Division of Anatomy, Medical University of Vienna, Vienna, Austria.
  • Weninger WJ; Center for Anatomy and Cell Biology, Division of Anatomy, Medical University of Vienna, Vienna, Austria.
  • Siddle K; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Willis AE; Medical Research Council Toxicology Unit, University of Leicester, Leicester, UK.
  • Lam BYH; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
  • Bushell M; Medical Research Council Toxicology Unit, University of Leicester, Leicester, UK.
  • Ozanne SE; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Centre for Trophoblast Research, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
  • Constância M; Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK; Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Centre fo
Cell Rep ; 43(9): 114750, 2024 Sep 24.
Article en En | MEDLINE | ID: mdl-39283743
ABSTRACT
Mir483 is a conserved and highly expressed microRNA in placental mammals, embedded within the Igf2 gene. Its expression is dysregulated in a number of human diseases, including metabolic disorders and certain cancers. Here, we investigate the developmental regulation and function of Mir483 in vivo. We find that Mir483 expression is dependent on Igf2 transcription and the regulation of the Igf2/H19 imprinting control region. Transgenic Mir483 overexpression in utero causes fetal, but not placental, growth restriction through insulin-like growth factor 1 (IGF1) and IGF2 and also causes cardiovascular defects leading to fetal death. Overexpression of Mir483 post-natally results in growth stunting through IGF1 repression, increased hepatic lipid production, and excessive adiposity. IGF1 infusion rescues the post-natal growth restriction. Our findings provide insights into the function of Mir483 as a growth suppressor and metabolic regulator and suggest that it evolved within the INS-IGF2-H19 transcriptional region to limit excessive tissue growth through repression of IGF signaling.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Factor II del Crecimiento Similar a la Insulina / MicroARNs Límite: Animals / Female / Humans / Pregnancy Idioma: En Revista: Cell Rep Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Factor II del Crecimiento Similar a la Insulina / MicroARNs Límite: Animals / Female / Humans / Pregnancy Idioma: En Revista: Cell Rep Año: 2024 Tipo del documento: Article